Neurisol (Gabapentin)

Gabapentin binds to the α2δ auxiliary subunit of voltage‑gated calcium channels in the central nervous system. This reduces calcium influx into presynaptic neurons, decreasing the release of excitatory neurotransmitters and thereby dampening neuronal hyperexcitability and pain signaling.

The appropriate dose of Neurisol is individualized by the prescribing clinician based on the specific indication, patient age, renal function, and response to therapy. No fixed regimen is provided here; dosing decisions are made by qualified healthcare professionals.

The safety of gabapentin in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and clinicians should weigh potential benefits against possible risks before prescribing to pregnant or nursing women.

To request Neurisol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both gabapentin (Neurisol) and pregabalin belong to the same class of calcium‑channel α2δ ligands and are used for neuropathic pain and seizures. Pregabalin generally has higher bioavailability and may require fewer daily doses, while gabapentin is often less expensive and has a broader range of approved indications.

Neurisol should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, heat and direct sunlight to maintain stability and potency.

Neurisol is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised.

Serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome, suicidal ideation, respiratory depression (especially when combined with other depressants), anaphylaxis, blood dyscrasias, and hepatic failure. Patients should be monitored closely for any of these signs.

Neurisol is contraindicated in patients with known hypersensitivity to gabapentin or any of the tablet excipients. Caution is also advised for individuals with severe renal impairment who have not had dose adjustments, and for those taking multiple central nervous system depressants without proper monitoring.